A study of ramantamig plus daratumumab versus investigator’s choice in participants with newly diagnosed multiple myeloma

ISRCTN ISRCTN15262649
DOI https://doi.org/10.1186/ISRCTN15262649
ClinicalTrials.gov (NCT) NCT07665450
Clinical Trials Information System (CTIS) 2026-526654-14
Integrated Research Application System (IRAS) 1014316
Central Portfolio Management System (CPMS) 73944
Sponsor's protocol code number 79635322MMY3004
Sponsor Janssen-Cilag International N.V.
Funder Janssen Research and Development
Submission date
02/07/2026
Registration date
24/08/2026
Last edited
27/10/2026
Recruitment status
Recruiting
Overall study status
Ongoing
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Newly diagnosed multiple myeloma (NDMM) is a blood cancer that forms in a type of white blood cells (WBCs) called plasma cells. Although treatment options are available, but either cancer can come back, it can cause harmful side effects or spread to other parts of body. Hence, there is a need for better treatment options. JNJ-79635322 (Ramantamig) binds to proteins called B-cell maturation antigen* and G protein-coupled receptor family C Group 5 member D* found mainly on cancer cells, and cluster of differentiation 3 (CD3) found on T-cells. Upon binding, it activates T-cells and leads to killing of cancer cells. *Protein found on cancer cells that new treatments can target to help fight the disease.

Who can participate?
Participants aged 18 years or older with NDMM who are not suitable for or not planned to receive a stem cell transplant.

What does the study involve?
1.Screening phase (up to 28 days)
2.Treatment phase (Start of treatment until treatment completion or discontinuation): Participants will be randomly (by chance) assigned to either:
•Arm A: Ramantamig-D
•Arm B: Either DVRd or DRd (investigator's choice)
3.Follow-up phase: Until death, withdrawal of consent, lost to follow-up, or end of the trial, whichever occurs first.

Safety assessments include adverse events, physical examinations, vital signs, electrocardiogram, clinical laboratory tests, suicide assessments, and tuberculosis screening. The overall duration of the study will be approximately 5 years

What are the possible benefits and risks of participating?
There is no established benefit to participants of this study. Based on scientific theory, taking Ramantamig-D may improve NDMM. However, this cannot be guaranteed because Ramantamig-D is still under investigation as a treatment and it is not known whether Ramantamig -D will work.
Participants may experience some benefit from participation in the study that is not due to receiving study drug, but due to regular visits and assessments monitoring overall health. Participation may help other people with NDMM in the future.
Participants may have side effects from the drugs or procedures used in this study that may be mild to severe and even life-threatening, and they can vary from person to person. Potential risks include cytokine release syndrome (CRS; inflammation condition that may occur after treatment with some types of immunotherapy), immune effector cell-associated neurotoxicity syndrome (ICANS; neurological side effects may occur that include headaches or a condition of brain), infections, Hypogammaglobulinemia (low protein in blood that fights infection), immune-mediated toxicity (hyperactive immune system attacks healthy tissues), harm to mouth, skin and nails, systemic administration-related reaction (sARRs; side effects caused due to administration of drug into the vein), injection site reactions, tumor lysis syndrome (TLS; large numbers of cancer cells die rapidly releasing their contents in to the blood stream), cytopenias (abnormally low number of blood cells). There are other, less frequent risks. The participant information sheet and informed consent form, which will be signed by every participant agreeing to participate in the study, includes a detailed section outlining the known risks to participating in the study.
Not all possible side effects and risks related to Ramantamig-D are known at this moment. During the study, the sponsor may learn new information about Ramantamig-D. The study doctor will tell participants as soon as possible about any new information that might make them change their mind about being in the study, such as new risks.
To minimise the risk associated with taking part in the study, participants are frequently reviewed for any side effects and other medical events. Participants are educated to report any such events to their study doctor who will provide appropriate medical care. Any serious side effects that are reported to the sponsor are thoroughly reviewed by a specialist drug safety team.
There are no costs to participants to be in the study. The sponsor will pay for the study drug and tests that are part of the study. The participant will receive reasonable reimbursement for study-related costs (e.g., travel/parking costs).

Where is the study run from?
Janssen-Cilag International NV (Netherlands)

When is the study starting and how long is it expected to run for?
September 2026 to February 2035

Who is funding the study?
Janssen Research and Development LLC (USA)

Who is the main contact?
medinfo@its.jnj.com

Contact information

Medical Information and Product Information Enquiry
Scientific, Public

Janssen Research & Development (Janssen-Cilag Ltd), 20 Grenfell Road
Maidenhead
SL6 1EH
United Kingdom

Phone +44 800 731 8450 / 10494 567 444
Email medinfo@its.jnj.com
Dr Jindriska Lindsay
Principal investigator

Kent and Canterbury Hospital, Ethelbert Road
Canterbury
CT1 3NG
United Kingdom

Study information

Primary study designInterventional
AllocationRandomized controlled trial
MaskingOpen (masking not used)
ControlActive
AssignmentParallel
PurposeSafety
Scientific titleA phase 3 randomized study comparing ramantamig plus daratumumab versus investigator’s choice of daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) or daratumumab, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma for whom hematopoietic stem cell transplant is not planned as initial therapy
Study acronymTRIlogy-7
Study objectives Main objectives:
To find out whether using ramantamig along with daratumumab can- help participants with NDMM live longer without the disease getting worse and- have no signs of cancer after 12 months of treatment, compared to standard treatment of DVRd or DRd in participants who are not suitable for or not planned to receive a stem cell transplant
Secondary objectives:
1.To assess whether ramantamig-D can help patients with newly diagnosed multiple myeloma live longer (overall survival) compared to standard treatment of DVRd or DRd in participants who are not suitable for or not planned to receive a stem cell transplant
2.To find out whether ramantamig-D will improve 24-month sustained minimal residual disease (MRD) negative complete response rate. MRD is a situation where there are no detectable signs of remaining cancer cells for at least 24 months
3. To compare how well ramantamig-D works compared to standard treatments (DVRd or DRd)
4. To further understand how safe ramantamig-D is
5. To learn how participants feel and function during treatment, including their overall well-being (health-related quality of life), using participant questionnaires
6. To understand how well participants are able to tolerate (manage) treatment with ramantamig-D
Ethics approval(s)

Approved 18/08/2026, North West – Haydock REC (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; -; haydock.rec@hra.nhs.uk), ref: 26/NW/0213

Health condition(s) or problem(s) studiedNewly diagnosed multiple myeloma
InterventionExperimental: Arm A: Ramantamig plus Daratumumab (Ramantamig-D)
Participants will receive ramantamig D subcutaneous injection.

Active Comparator: Arm B: Investigator's Choice (DVRd or DRd)
Participants will receive either daratumumab, bortezomib, lenalidomide, dexamethasone (DVRd) or daratumumab, lenalidomide, dexamethasone (DRd) as per investigator's choice.
Daratumumab will be administered subcutaneously.
Lenalidomide will be administered orally.
Bortezomib will be administered subcutaneously or intravenously.
Dexamethasone will be administered orally or intravenously.
Intervention typeDrug
PhasePhase III
Drug / device / biological / vaccine name(s)Ramantamig, daratumumab, lenolidomide, bortezomib, dexamethosone
Primary outcome measure(s)

Current primary outcome(s) as of 27/10/2026:

1. Progression-Free Survival (PFS)
PFS is defined as the duration from randomization to either confirmed progression of disease (PD) or death, whichever occurs first up to 62 months
2. Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response (CR) 12-month MRD-negative CR rate is defined as participants who achieve MRD-negative status at 12 months (+/-3 months) from randomization, as determined by next-generation sequencing (NGS), prior to PD or subsequent antimyeloma therapy (including ASCT). Additionally, participant must achieve CR or better any time from randomization up to and including 12+3 months prior to PD or subsequent antimyeloma therapy, according to international myeloma working group (IMWG) criteria up to 12 months

_____

Previous primary outcome(s):

1. Progression-Free Survival (PFS). PFS is defined as the time from treatment assignment (that is, randomisation in the trial) to confirmed progression of disease (PD) or death, whichever occurs first up to approx 62 months
2. Percentage of Participants Achieving 12-Month Minimal Residual Disease (MRD)-Negative Complete Response CR 12-month MRD-negative CR rate is defined as achieving MRD-negative status at the analysis time window of 12 months (+/-3 months), as determined by next-generation sequencing (NGS) with sensitivity of 10^-5, prior to PD or subsequent antimyeloma therapy (including ASCT). Additionally, CR or better must be achieved any time from randomisation up to and including 12+3 months, according to international myeloma working group (IMWG) criteria up to 12 months

Key secondary outcome measure(s)

Current key secondary outcome(s) as of 27/10/2026:

1. Overall survival (OS): Overall survival is defined as the time from treatment assignment (that is, randomization in the trial) to death from any cause. Assessed up to approximately 100 months
2. Percentage of Participants Achieving 24-Month Sustained MRD-Negative CR
24-month sustained MRD-negative CR is defined as participants who achieve MRD-negative CR status, as determined by NGS for at least 24 months without any examination showing MRD positive status or PD in between up to 5 years
3. Percentage of participants with very good partial response (VGPR) or better: Percentage of participants achieving VGPR, CR, or stringent complete response (sCR) before receiving subsequent antimyeloma therapy, in accordance with International Myeloma Working Group (IMWG) criteria, during or after the trial intervention. Assessed up to 5 years
4. Percentage of participants achieving CR or sCR: Percentage of participants achieving CR or sCR before receiving subsequent antimyeloma therapy, in accordance with IMWG criteria, during or after the trial intervention. Assessed up to 5 years
5. Percentage of participants with overall response: Percentage of participants achieving partial response (PR) or better before receiving subsequent antimyeloma therapy, in accordance with IMWG criteria, during or after the trial intervention. Assessed up to 5 years
6. Percentage of participants with overall MRD-negative CR: Percentage of participants who achieve MRD-negative status, as determined by next-generation sequencing (NGS), at any time after randomization and before PD or subsequent antimyeloma therapy, and who achieve CR or better. Assessed up to 5 years
7. Percentage of Participants with 12-Month Sustained MRD-Negative CR
Percentage of participants who achieve MRD-negative CR status, as determined by NGS, for at least 12 months without any examination showing MRD-positive status or PD in between will be reported up to 5 years
8. Progression-free survival 2 (PFS2): PFS2 is defined as the time from randomization to PD on the first subsequent line of antimyeloma therapy, as assessed by the investigator, or death from any cause, whichever occurs first. Assessed up to approximately 100 months
9. Number of participants with adverse events (AEs): An adverse event is any untoward medical occurrence in a participant receiving a pharmaceutical product, whether investigational or non-investigational, and does not necessarily have a causal relationship with the intervention. Assessed up to approximately 100 months
10. Change from baseline in health-related quality of life (HRQoL) assessed by the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q): The MySIm-Q is a disease-specific patient-reported outcome measure complementary to the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). It contains 17 items with a 7-day recall period and responses scored from 0 to 4, with higher scores indicating greater symptom severity or impact. Assessed up to approximately 100 months
11. Change from baseline in HRQoL assessed by the EORTC QLQ-C30: The EORTC QLQ-C30 Version 3 contains 30 items covering functional scales, global health status, symptom scales, and individual symptom items. Scores are transformed to a 0 to 100 scale. Higher scores represent better HRQoL and functioning, and more severe symptoms where applicable. Assessed up to approximately 100 months
12. Change from baseline in HRQoL assessed by the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L): The EQ-5D-5L is a self-administered generic health status measure comprising a descriptive system and a visual analogue scale. It assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher scores indicate worse HRQoL. Assessed up to approximately 100 months
13. Change from baseline in HRQoL assessed by the Patient Global Impression of Symptom Severity (PGIS): The PGIS is a 2-item questionnaire assessing symptom severity and the impact of symptoms on a 5-point verbal rating scale. Scores range from 1 (none) to 5 (very severe), with higher scores indicating greater symptom severity. Assessed up to approximately 100 months
14. Change from baseline in HRQoL assessed by the European Organisation for Research and Treatment of Cancer Item List 46 (EORTC IL46): The EORTC IL46 consists of a single question measuring the overall burden of treatment-related symptoms. Responses range from "not at all" to "very much" on a 4-point scale, with higher scores indicating greater symptom burden. Assessed up to approximately 100 months
15. Percentage of participants with tolerability to ramantamig-D measured through patient-reported outcomes (PROs): Percentage of participants with tolerability to ramantamig-D as measured through patient-reported outcomes. Assessed up to approximately 100 months

_____

Previous key secondary outcome(s):

1. Overall survival (OS): Overall survival is defined as the time from treatment assignment (that is, randomization in the trial) to death from any cause. Assessed up to approximately 100 months
2. Percentage of participants achieving 24-month sustained MRD-negative complete response (CR): 24-month sustained MRD-negative CR is defined as achieving confirmed CR or better while maintaining MRD-negative status for at least 24 months without any examination showing MRD-positive status or progressive disease (PD) in between. Assessed up to 5 years
3. Percentage of participants with very good partial response (VGPR) or better: Percentage of participants achieving VGPR, CR, or stringent complete response (sCR) before receiving subsequent antimyeloma therapy, in accordance with International Myeloma Working Group (IMWG) criteria, during or after the trial intervention. Assessed up to 5 years
4. Percentage of participants achieving CR or sCR: Percentage of participants achieving CR or sCR before receiving subsequent antimyeloma therapy, in accordance with IMWG criteria, during or after the trial intervention. Assessed up to 5 years
5. Percentage of participants with overall response: Percentage of participants achieving partial response (PR) or better before receiving subsequent antimyeloma therapy, in accordance with IMWG criteria, during or after the trial intervention. Assessed up to 5 years
6. Percentage of participants with overall MRD-negative CR: Percentage of participants who achieve MRD-negative status, as determined by next-generation sequencing (NGS), at any time after randomization and before PD or subsequent antimyeloma therapy, and who achieve CR or better. Assessed up to 5 years
7. Percentage of participants with 12-month sustained MRD-negative CR: Percentage of participants with confirmed CR or better who maintain MRD-negative status, as determined by NGS, for at least 12 months without any examination showing MRD-positive status or PD in between. Assessed up to 5 years
8. Progression-free survival 2 (PFS2): PFS2 is defined as the time from randomization to PD on the first subsequent line of antimyeloma therapy, as assessed by the investigator, or death from any cause, whichever occurs first. Assessed up to approximately 100 months
9. Number of participants with adverse events (AEs): An adverse event is any untoward medical occurrence in a participant receiving a pharmaceutical product, whether investigational or non-investigational, and does not necessarily have a causal relationship with the intervention. Assessed up to approximately 100 months
10. Change from baseline in health-related quality of life (HRQoL) assessed by the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q): The MySIm-Q is a disease-specific patient-reported outcome measure complementary to the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). It contains 17 items with a 7-day recall period and responses scored from 0 to 4, with higher scores indicating greater symptom severity or impact. Assessed up to approximately 100 months
11. Change from baseline in HRQoL assessed by the EORTC QLQ-C30: The EORTC QLQ-C30 Version 3 contains 30 items covering functional scales, global health status, symptom scales, and individual symptom items. Scores are transformed to a 0 to 100 scale. Higher scores represent better HRQoL and functioning, and more severe symptoms where applicable. Assessed up to approximately 100 months
12. Change from baseline in HRQoL assessed by the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L): The EQ-5D-5L is a self-administered generic health status measure comprising a descriptive system and a visual analogue scale. It assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Higher scores indicate worse HRQoL. Assessed up to approximately 100 months
13. Change from baseline in HRQoL assessed by the Patient Global Impression of Symptom Severity (PGIS): The PGIS is a 2-item questionnaire assessing symptom severity and the impact of symptoms on a 5-point verbal rating scale. Scores range from 1 (none) to 5 (very severe), with higher scores indicating greater symptom severity. Assessed up to approximately 100 months
14. Change from baseline in HRQoL assessed by the European Organisation for Research and Treatment of Cancer Item List 46 (EORTC IL46): The EORTC IL46 consists of a single question measuring the overall burden of treatment-related symptoms. Responses range from "not at all" to "very much" on a 4-point scale, with higher scores indicating greater symptom burden. Assessed up to approximately 100 months
15. Percentage of participants with tolerability to ramantamig-D measured through patient-reported outcomes (PROs): Percentage of participants with tolerability to ramantamig-D as measured through patient-reported outcomes. Assessed up to approximately 100 months

Completion date02/02/2035

Eligibility

Participant type(s)
Age groupMixed
Lower age limit18 Years
Upper age limit120 Years
SexAll
Target sample size at registration1000
Key inclusion criteriaCurrent key inclusion criteria as of 27/10/2026:

1. Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria
2. Not considered for high-dose chemotherapy with autologous stem cell transplantation (ASCT) due to:
i. ineligible due to advanced age; or
ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT
3. Have an eastern cooperative oncology status (ECOG) performance status
of 0 to 2
4. Must sign an informed consent form (ICF)
5. Measurable disease at screening as assessed by central laboratory as defined in the protocol

_____

Previous key inclusion criteria:

1. Documented diagnosis of multiple myeloma (MM) according to the IMWG diagnostic criteria
2. Not considered for high-dose chemotherapy with autologous stem cell
transplantation (ASCT) due to:
i. ineligible due to advanced age; or
ii. ineligible due to presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT; or
iii. deferral of high-dose chemotherapy with ASCT as initial treatment
3. Have an eastern cooperative oncology status (ECOG) performance status of 0 to 2
4. Must sign an informed consent form (ICF)
5. Measurable disease at screening as assessed by central laboratory as defined in the protocol
Key exclusion criteriaCurrent key exclusion criteria as of 27/10/2026:

1. Myeloma Frailty Score of greater than or equal to (>=) 2 with the exception of participants who have a score of 2 based on age alone
2. Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients
3. Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose of trial intervention or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial
4. Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM
5. Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids

_____

Previous key exclusion criteria:

1. Myeloma Frailty Score of greater than or equal to (>=) 2 with the exception of participants who have a score of 2 based on age alone
2. Suspected or known allergies, hypersensitivity, intolerance or other contraindications to any trial intervention or its excipients
3. Had major surgery (for example, requiring general anesthesia) or had significant traumatic injury within 2 weeks prior to first dose or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the trial
4. Known active or prior CNS involvement or exhibits clinical signs of meningeal involvement of MM
5. Received any prior therapy(ies) for treatment of MM or smoldering myeloma, with the exception of emergency use of a short course of corticosteroids
Date of first enrolment23/09/2026
Date of final enrolment15/08/2028

Locations

Countries of recruitment

  • United Kingdom
  • England
  • Scotland
  • Australia
  • Brazil
  • China
  • Czech Republic
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Japan
  • Netherlands
  • Poland
  • Portugal
  • Spain
  • United States of America

Study participating centres

Kent and Canterbury Hospital
Ethelbert Road
Canterbury
CT1 3NG
England
Blackpool Victoria Hospital
Whinney Heys Road
Blackpool
FY3 8NR
England
New Cross Hospital
Wolverhampton Road
Heath Town
Wolverhampton
WV10 0QP
England
Addenbrookes Hospital
Hills Road
Cambridge
CB2 0QQ
England
Western General Hospital
Crewe Road South
Edinburgh
Lothian
EH4 2XU
Scotland
University Hospital Bristol and Weston, Bristol Haematology and Oncology Centre
Horfield Road
Bristol
BS2 8ED
England
University College Hospital, Cancer Clinical Trials Unit
250 Euston Road
London
NW1 2PG
England
University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Hospital
Mindelsohn Way
Edgbaston
Birmingham
B15 2GW
England
Colchester General Hospital
Turner Road
Colchester
CO4 5JL
England

Results and Publications

Individual participant data (IPD) Intention to shareYes
IPD sharing planThe data sharing policy of Johnson & Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Editorial Notes

27/10/2026: The following changes were made to the study record:
1. The date of first enrolment was changed from 28/10/2026 to 23/09/2026.
2. The primary outcome(s) were changed.
3. The key secondary outcome(s) were changed.
4. The key inclusion criteria were changed.
5. The key exclusion criteria were changed.
6. Contact details updated.
25/09/2026: Internal review.
08/09/2026: Ethics approval details added. The date of first enrolment was changed from 13/09/2026 to 28/10/2026.
22/08/2026: ISRCTN received notification of combined HRA/MHRA approval for this trial on 22/08/2026.
02/07/2026: Trial's existence confirmed by NHS HRA.